| Literature DB >> 33986629 |
Shan Tu1, Zhi-Jie Shen1, Xiao-Yan Wang1, Li-Xiong Zeng1, Zhi-Hui Zhang1.
Abstract
This study explored the effects of renal sympathetic denervation (RDN) on hyperlipidity-induced cardiac hypertrophy in beagle dogs. Sixty beagles were randomly assigned to the control group, RDN group, or sham-operated group. The control group was fed with a basal diet, while the other two groups were given a high-fat diet to induce model hypertension. The RDN group underwent an RDN procedure, and the sham-operated group underwent only renal arteriography. At 1, 3, and 6 months after the RDN procedure, the diastolic blood pressure (DBP) and systolic blood pressure (SBP) levels were markedly decreased in the RDN group relative to the sham group (P < 0.05). After 6 months, serum norepinephrine (NE) and angiotensin II (AngII), as well as left ventricular levels, in the RDN group were statistically lower than those in the sham group (P < 0.05). Also, the left ventricular mass (LVM) and left ventricular mass index (LVMI) were significantly decreased, while the E/A peak ratio was drastically elevated (P < 0.05). Pathological examination showed that the degree of left ventricular hypertrophy and fibrosis in the RDN group was statistically decreased relative to those of the sham group and that the collagen volume fraction (CVF) and perivascular circumferential collagen area (PVCA) were also significantly reduced (P < 0.05). Renal sympathetic denervation not only effectively reduced blood pressure levels in hypertensive dogs but also reduced left ventricular hypertrophy and myocardial fibrosis and improved left ventricular diastolic function. The underlying mechanisms may involve a reduction of NE and AngII levels in the circulation and myocardial tissues, which would lead to the delayed occurrence of left ventricular remodeling.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33986629 PMCID: PMC8093032 DOI: 10.1155/2021/9938486
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Changes in body weight, heart rate, blood pressure, blood lipid levels, and renal function in experimental dogs (control group (n = 20), sham-operated group (n = 19), and RDN group ()).
| Group | BW (kg) | HR (times/min) | SBP (mmHg) | DBP (mmHg) | TC (mmol/l) | TG (mmol/l) | LDL (mmol/l) | Cr (mg/dl) | CC (mmol/l) |
|---|---|---|---|---|---|---|---|---|---|
| Control group | |||||||||
| Baseline | 12.3 ± 1.9 | 132.7 ± 23.9 | 125.7 ± 6.0 | 73.6 ± 6.0 | 5.12 ± 0.82 | 0.44 ± 0.12 | 0.11 ± 0.03 | 55.83 ± 10.08 | 0.21 ± 0.03 |
| Preprocedure | 13.1 ± 1.2 | 124.3 ± 6.0 | 129.7 ± 6.8 | 75.3 ± 10.6 | 4.80 ± 0.57 | 0.47 ± 0.20 | 0.09 ± 0.03 | 52.83 ± 15.22 | 0.20 ± 0.03 |
| 1 month | 13.2 ± 1.1 | 122.9 ± 17.61 | 130.8 ± 6.5 | 77.3 ± 13.4 | 50.33 ± 7.58 | 0.16 ± 0.04 | |||
| 3 months | 13.3 ± 1.0 | 125.4 ± 18.26 | 130.8 ± 6.5 | 81.6 ± 4.6 | 48.00 ± 8.22 | 0.17 ± 0.03 | |||
| 6 months | 13.3 ± 0.8 | 124.3 ± 21.57 | 127.8 ± 3.6 | 78.2 ± 7.4 | 4.95 ± 0.47 | 0.49 ± 0.14 | 0.10 ± 0.04 | 54.00 ± 2.28 | 0.18 ± 0.03 |
| Sham-operated group | |||||||||
| Baseline | 12.3 ± 0.5 | 129.6 ± 11.7 | 124.7 ± 8.2 | 76.4 ± 8.4 | 5.41 ± 0.81 | 0.46 ± 0.09 | 0.10 ± 0.02 | 57.75 ± 6.75 | 0.21 ± 0.03 |
| Preprocedure | 17.5 ± 2.7ab | 141.3 ± 13.5 | 151.6 ± 12.3ab | 95.1 ± 9.2ab | 7.73 ± 1.20ab | 0.56 ± 0.18ab | 0.21 ± 0.08ab | 52.37 ± 9.05 | 0.20 ± 0.05 |
| 1 month | 17.6 ± 2.9ab | 136.5 ± 8.72 | 153.7 ± 13.7ab | 93.2 ± 12.1ab | 51.50 ± 7.91 | 0.18 ± 0.05 | |||
| 3 months | 18.3 ± 1.8ab | 140.5 ± 17.17 | 152.5 ± 12.6ab | 91.6 ± 9.7ab | 53.25 ± 5.57 | 0.19 ± 0.04 | |||
| 6 months | 18.5 ± 1.9ab | 143.9 ± 18.01 | 155.8 ± 8.5ab | 95.8 ± 16.0ab | 7.95 ± 1.14ab | 0.61 ± 0.15ab | 0.20 ± 0.05ab | 54.25 ± 3.69 | 0.20 ± 0.03 |
| RDN group | |||||||||
| Baseline | 11.8 ± 0.8 | 131.5 ± 10.7 | 123.7 ± 10 | 77.1 ± 9.6 | 5.41 ± 0.81 | 0.50 ± 0.13 | 0.12 ± 0.05 | 53.33 ± 12.32 | 0.21 ± 0.05 |
| Preprocedure | 17.6 ± 2.0ab | 143.7 ± 14.2 | 153.1 ± 9.5ab | 92.5 ± 7.6ab | 7.84 ± 0.88ab | 0.56 ± 0.12ab | 0.23 ± 0.06ab | 47.22 ± 12.39 | 0.21 ± 0.05 |
| 1 month | 17.7 ± 2.1ab | 133.3 ± 12.76 | 134.6 ± 8.4cd | 82.9 ± 7.0cd | 46.22 ± 6.94 | 0.16 ± 0.04 | |||
| 3 months | 17.9 ± 2.4ab | 131.4 ± 15.08 | 131.4 ± 10.4cd | 82.9 ± 7.0cd | 47.00 ± 7.48 | 0.17 ± 0.03 | |||
| 6 months | 18.6 ± 2.3ab | 131.2 ± 22.18 | 129.6 ± 8.4cd | 79.4 ± 5.3cd | 7.23 ± 1.27ab | 0.56 ± 0.13ab | 0.18 ± 0.07ab | 50.44 ± 4.58 | 0.18 ± 0.03 |
aCompared with baseline, P < 0.05. bCompared with the control group, P < 0.05. cCompared with the sham-operated group, P < 0.05. dCompared with preprocedure, P < 0.05. BW: body weight; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglycerides; LDL: low-density lipoprotein; Cr: creatinine; CC: cystatin C.
Figure 2RDN procedure: (a) right renal arteriography before ablation; (b) ablation of lower wall of the right renal artery; (c) ablation of anterior wall of the right renal artery; (d) ablation of posterior wall of the right renal artery; (e) ablation of upper wall of the right renal artery; (f) right renal arteriography after ablation.
Changes in levels of norepinephrine (NE) and angiotensin II (AngII) in experimental dogs (control group (n = 20), sham-operated group (n = 19), and RDN group ()).
| Group | NE (pg/ml) | AngII (pg/ml) | Myocardial NE (pg/mg) | Myocardial AngII (pg/mg) |
|---|---|---|---|---|
| Control group | ||||
| Baseline | 123.36 ± 80.16 | 66.48 ± 5.19 | ||
| Preprocedure | 141.13 ± 52.17 | 67.84 ± 8.03 | ||
| 6 months | 180.82 ± 77.03 | 69.33 ± 2.58 | 1953.5 ± 606.7 | 963.0 ± 192.2 |
| Sham-operated group | ||||
| Baseline | 140.16 ± 70.63 | 63.40 ± 8.80 | ||
| Preprocedure | 553.2 ± 202.90ab | 130.40 ± 8.3ab | ||
| 6 months | 609.20 ± 144.36ab | 136.20 ± 6.27ab | 4343.6 ± 346.4b | 1217.1 ± 186.9b |
| RDN group | ||||
| Baseline | 106.12 ± 52.01 | 63.31 ± 7.19 | ||
| Preprocedure | 531.07 ± 159.58ab | 122.74 ± 10.78ab | ||
| 6 months | 299.45 ± 97.08acd | 88.49 ± 5.69acd | 2272.9 ± 774.0c | 1077.8 ± 196.0c |
aCompared with baseline, P < 0.05. bCompared with the control group, P < 0.05. cCompared with the sham-operated group, P < 0.05. dCompared with preprocedure, P < 0.05.
Figure 1Changes in blood pressure, left ventricular mass (LVM), peak E/A ratio, norepinephrine (NE), and angiotensin II (AngII) in experimental dogs. ACompared with baseline, P < 0.05. BCompared with the control group, P < 0.05. CCompared with the sham group, P < 0.05. DCompared with preprocedure, P < 0.05.
Echocardiographic evaluation of structural cardiac changes in experimental dogs (control group (n = 20), sham-operated group (n = 19), and RDN group ()).
| Group | LVEDD (mm) | IVST (mm) | LVPW (mm) | LVM (g) | LVMI (g/kg) | LVEF (%) (cm/s) | Peak E (cm/s) | Peak A (cm/s) | Peak E/A | LAD (mm) |
|---|---|---|---|---|---|---|---|---|---|---|
| Control group | ||||||||||
| Baseline | 25.7 ± 1.0 | 6.33 ± 0.5 | 6.0 (5.0-7.0) | 30.7 ± 3.4 | 2.49 ± 0.1 | 61.2 ± 2.2 | 0.68 ± 0.2 | 0.52 ± 0.1 | 1.32 ± 0.1 | 19.8 ± 1.8 |
| Preprocedure | 25.3 ± 1.4 | 6.17 ± 0.4 | 6.0 (6.0-7.0) | 30.9 ± 2.8 | 2.48 ± 0.2 | 60.3 ± 5.9 | 0.74 ± 0.1 | 0.63 ± 0.1 | 1.17 ± 0.3 | 21.0 ± 1.6 |
| 6 months | 25.6 ± 1.5 | 6.0 ± 0.6 | 6.0 (6.0-7.0) | 32.2 ± 2.8 | 2.35 ± 0.1 | 62.8 ± 5.0 | 0.79 ± 0.1 | 0.66 ± 0.1 | 1.20 ± 0.1 | 20.6 ± 1.5 |
| Sham-operated group | ||||||||||
| Baseline | 25.6 ± 1.0 | 6.50 ± 0.5 | 6.0 (6.0-7.0) | 31.9 ± 4.2 | 2.57 ± 0.3 | 61.6 ± 1.9 | 0.68 ± 0.1 | 0.51 ± 0.1 | 1.31 ± 0.1 | 19.5 ± 1.1 |
| Preprocedure | 28.6 ± 1.3ad | 9.88 ± 0.6ad | 8.0 (7.0-8.0)ad | 62.8 ± 5.9ad | 3.62 ± 0.4ad | 64.2 ± 3.6 | 0.54 ± 0.1ad | 0.59 ± 0.1 | 0.91 ± 0.1ad | 20.5 ± 1.3 |
| 6 months | 28.1 ± 1.1ad | 10.0 ± 0.6ad | 8.0 (7.0-9.0)ad | 65.1 ± 4.3ad | 3.63 ± 0.6ad | 61.8 ± 4.1 | 0.48 ± 0.1ad | 0.55 ± 0.1ad | 0.87 ± 0.4ad | 25.3 ± 1.6ad |
| RDN group | ||||||||||
| Baseline | 25.1 ± 1.0 | 6.64 ± 0.5 | 6.0 (5.0-7.0) | 32.0 ± 4.5 | 2.69 ± 0.2 | 62.0 ± 1.9 | 0.68 ± 0.1 | 0.51 ± 0.1 | 1.27 ± 0.1 | 19.8 ± 1.4 |
| Preprocedure | 29.1 ± 1.0ad | 10.0 ± 0.7ad | 7.0 (7.0-8.0)ad | 62.3 ± 5.2ad | 3.57 ± 0.5ad | 62.0 ± 2.2 | 0.48 ± 0.1ad | 0.57 ± 0.1 | 0.83 ± 0.1ad | 20.5 ± 1.2 |
| 6 months | 29.7 ± 1.9ad | 8.6 ± 0.8bc | 6.1 (6.0-7.0)bc | 52.2 ± 4.4bc | 2.82 ± 0.1bc | 62.3 ± 3.1 | 0.70 ± 0.1bc | 0.56 ± 0.1 | 1.25 ± 0.1bc | 21.1 ± 1.2 |
aCompared with baseline, P < 0.05. bCompared with preprocedure, P < 0.05. cCompared with the sham-operated group, P < 0.05. dCompared with the control group, P < 0.05. LVEDD: left ventricular end-diastolic diameter; IVST: interventricular septal thickness; LVPW: left ventricular posterior wall; LVM: left ventricular mass; LVMI: left ventricular mass index; LVEF: left ventricular ejection fraction; peak E: early peak diastolic velocity; peak A: peak atrial velocity; peak E/A: the ratio of peak E to peak A; LAD: left atrial diameter.
Figure 3Pathological changes in the left ventricular myocardium of experimental dogs. (a–c) HE staining of myocardial tissue (light microscopy, 400x): (a) normal myocardial tissue in the control group, (b) the RDN group, and (c) the sham-operated group. The size and cross-sectional area of cardiomyocytes were statistically smaller in the RDN group than in the sham-operated group. Additionally, cardiomyocytes in the RDN group were arranged in a more orderly manner, similar to the control group. (d–f) Electron microscopy images of myocardial tissue (12000x): (d) the control group, (e) the RDN group: a portion of cardiomyocyte myofilaments was dissolved and ruptured, and a fraction of the mitochondria became swollen, and (f) the sham-operated group: multifocal dissolution and fragmentation of the myofilaments were apparent, mitochondrial and cellular swelling was evident, and the numbers of the mitochondria and cells were markedly reduced. (g–i) Masson's trichrome staining of myocardial tissue (light microscopy, 400x): (g) the control group, (h) the RDN group: a small number of collagen fibers were deposited in the myocardial stroma, and (i) the sham-operated group: large numbers of collagen fibers were produced in the myocardial stroma (red indicates cardiomyocytes, blue indicates collagen fibers, and red arrow points to collagen fiber). (j–l) Masson's trichrome staining of myocardial tissue (light microscopy, 400x): (j) the control group, (k) the RDN group: a small number of collagen fibers were deposited in the perivascular area, and (l) the sham-operated group: large numbers of collagen fibers were produced in the perivascular area (red indicates cardiomyocytes, blue indicates collagen fibers, and red arrow points to collagen fiber).
Changes in collagen volume fraction (CVF) and perivascular circumferential collagen area (PVCA) in the left ventricular myocardium in experimental dogs ().
| Group | Parameters | |
|---|---|---|
| CVF (%) | PVCA | |
| Control ( | 2.241 ± 0.67 | 0.67 ± 0.11 |
| Surgically treated ( | 4.32 ± 1.33a | 0.85 ± 0.16 |
| Sham-operated ( | 12.65 ± 1.67ab | 1.11 ± 0.19ab |
aCompared with the control group, P < 0.05. bCompared with the RDN group, P < 0.05.